GLP1R and cardiovascular disorder: The HARMONY trial with modified human GLP-1 receptor agonist albiglutide showed a reduction in three-point MACE driven mainly by a significant decrease in myocardial infarction by 25% in 9469 patients with T2DM and a history of cardiovascular disease [38].